A Promising Step for Prostate Cancer Treatment

Description

Early detection and treatment are critical for prostate cancer—the third-highest cause of cancer-related deaths in men. Recently, PET imaging using PSMA ligands has gained attention as a promising new radiotracer in these patients. Hear from the experts as they discuss implications around this game-changer in prostate cancer treatment.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Recognize the important diagnostic and management challenges in prostate cancer
  2. List the challenges and limitations involved in the applications of PET tracers.
  3. Assess the issues and limitations of F18 choline PET/CT imaging in preoperative staging and of F18 fluoride PET/CT in follow-up management.
  4. Describe and compare the pros and cons of Ga68/F18 PSMA radiolabeling and compare sensitivity and specificity of Ga68/F18 PSMA vs. other prostate tracers.
  5. Summarize the advantages of labeled PSMA in primary and biochemical recurrent prostate cancer and discuss how Ga68/F18 PSMA imaging can change patient management.
  6. Define the mechanism of action and provide warnings and precautions, adverse reactions, and potential drug interactions of Lu177 PSMA.
  7. Identify the significant outcomes from this novel therapy.
 

Joint Providership

This activity is approved for Board Certified Nuclear Pharmacist (BCNP) recertification credits.

 
 
Speakers:
FATEMEH
FATEMEH BEHNIA, MD
PHYSICIAN
UWMC
 
Langton-Webster
Langton-Webster Beatrice, PhD
Chief Executive Officer
Cancer Targeted Technology
 
Henry
Henry VanBrocklin, Ph.D., FSNMMI
Professor
University of California San Francisco
 
Learning Level: Level 2
Track: Nuclear Pharmacy
Session Time Slot(s): 
Date: 
Saturday, March 23
Time: 
3:00 PM - 6:00 PM
Room: 
Washington State Convention Center - Room 615-617
ACPE Pharmacist: 0202-0000-19-041-L04-P
CEUs Pharmacist: .3
Activity Type:
Knowledge-based